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OBJECTIVE— The purpose of this study was to estimate whether prevalence of metabolic
syndrome in adult European diabetic patients is associated with type of diabetes.
RESEARCH DESIGN AND METHODS— A consecutive series of patients attending
hospital-based diabetes clinics were assessed for the frequency of metabolic syndrome and
compared with population-based control subjects as part of the Action LADA study. In total,
2,011 subjects (aged 30–70 years) were studied, including 1,247 patients with recent-onset type
2 diabetes without glutamic acid decarboxylase autoantibodies (GADAs), 117 non–insulin-
requiring patients with GADAs who had not received insulin therapy for at least 6 months after
diagnosis (designated latent autoimmune diabetes of adults [LADA]), 288 type 1 diabetic pa-
tients, and 359 normal subjects.
RESULTS— Frequency of metabolic syndrome was significantly different in patients with
type 1 diabetes (31.9%) and LADA (41.9%) (P 0.015) and in both conditions was less frequent
than in type 2 diabetic patients (88.8%) (P 0.0001 for each). Eliminating glucose as a variable,
the prevalence of metabolic syndrome was similar in patients with autoimmune diabetes (type 1
diabetes and/or LADA) (17.3%) and control subjects (23.7%) but remained more common in
type 2 diabetic patients (47.8%) (P 0.001 for all groups). In both type 1 diabetic patients and
those with LADA, individual components of metabolic syndrome were similar but less common
than in type 2 diabetic patients (P  0.0001 for each).
CONCLUSIONS— The prevalence of metabolic syndrome is significantly higher in type 2
diabetic patients than in patients with LADA or adults with type 1 diabetes. Excluding glucose as
a variable, metabolic syndrome is not more prevalent in patients with autoimmune diabetes than
in control subjects. Metabolic syndrome is not a characteristic of autoimmune diabetes.
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T ype 1 diabetes is an autoimmunedisease in which insulin deficiencyresults from immune-mediated de-
struction of insulin-secreting islet cells.
The majority of patients with type 1 di-
abetes have autoantibodies in their pe-
ripheral blood, and these autoantibodies
can predict the disease. Autoimmune di-
abetes, as characterized by these auto-
antibodies, such as glutamic acid
decarboxylase autoantibodies (GADAs),
is the most prevalent form of diabetes in
children and also occurs in a proportion
of patients who initially present with
adult-onset non–insulin-requiring diabe-
tes, also called latent adult-onset autoim-
mune diabetes (LADA) (1).
Because glucose disposal and blood
glucose are determined by both insulin
secretion and insulin action, it follows
that insulin sensitivity could be important
in the pathogenesis of autoimmune dia-
betes. Insulin sensitivity has not been
studied in detail in autoimmune diabetes,
although studies suggest that its loss may
occur in established disease as well as in
the pre-diabetic phase (2–5). Loss of in-
sulin sensitivity is difficult to assess epi-
demiologically but is reflected in the
cluster of metabolically related cardiovas-
cular risk factors that together comprise
the metabolic syndrome and include al-
tered glucose levels, central obesity, dys-
lipidemia, and hypertension. Several
groups, including the International Dia-
betes Federation (IDF) and the National
Cholesterol Education Program (NCEP),
with Adult Treatment Panel III (6), have
proposed their own definitions for the
metabolic syndrome.
LADA is clearly distinct from type 2
diabetes, in that LADA is associated with
histocompatability (HLA) genes, diabe-
tes-associated autoantibodies, reduced
insulin secretion, no need for insulin ther-
apy initially after diagnosis, and less prev-
alence of metabolic syndrome (7–9). The
key question is whether LADA is distinct
from type 1 diabetes (1,10,11), that is,
whether LADA is one end of a rainbow of
pathophysiological variations encom-
passing autoimmune diabetes with a fre-
quency of metabolic syndrome similar to
that of childhood-onset type 1 diabetes or
whether LADA is a distinct form of auto-
immune diabetes that resembles type 2
diabetes, showing evidence of insulin re-
sistance with a high frequency of meta-
bolic syndrome (1). Therefore, the aim of
this study was to test whether individuals
with type 2 diabetes and autoimmune di-
abetes (incorporating type 1 diabetes and
LADA) have a higher frequency of meta-
bolic syndrome than normal subjects, and
our hypothesis was that they would.
RESEARCH DESIGN AND
METHODS— The study design is
cross-sectional and includes adult dia-
betic patients and control subjects (aged
30–70 years) from five European cities
(London, Belfast, Lyon, Barcelona, and
Rome) examined between 2004 and
2007. All patients came from five Euro-
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pean hospital-based centers involved in
Action LADA, a European Union–funded
multicenter European study with the aim
of identifying immune and clinical risk
factors for adult-onset autoimmune dia-
betes (http://www.actionlada.org). Dia-
betes was designated according to
standard criteria, and LADA was defined
as patients aged 30–70 years with GADAs
who did not require insulin treatment for
at least 6 months after diagnosis (7,8).
Type 1 diabetic patients and normal sub-
jects fulfilling the inclusion criteria were
ascertained consecutively from three of
these five European centers (London,
Barcelona, and Rome). The control sub-
jects came from health centers in local
communities.
Inclusion criteria were diagnosis of
diabetes (with at least two fasting blood
glucose measurements 7 mmol/l), time
from diagnosis 5 years for all non–
insulin-requiring diabetic patients, and
age 30–70 years at examination. Patients
came from Europe but with different eth-
nicity (91.7% Caucasian, 4.6% Middle
Eastern, 1.4% Asian, 1.3% African, and
1.0% mixed race). Control subjects were
individuals from local communities at-
tending primary care centers for routine
examination with age range and sex ratio
similar to those of the patients and were
all Caucasian. Exclusion criteria for both
patients and control subjects were incom-
plete data set, current pregnancy, renal
disease with a raised creatinine level or
proteinuria, or acute illness at the time of
testing; in addition, patients with non–
insulin-requiring diabetes with duration
of5 years and control subjects with any
clinical disease, therapy, or family history
of autoimmune disease were excluded.
Data on medication and risk factors were
registered by the attending physician on
the basis of the medical files. Serum and
plasma samples were collected according
to standard procedures and were stored at
80°C.
Each subject was tested locally for
waist circumference and blood pressure.
Blood pressure was measured at least
twice in the sitting position. Lipids and
lipoproteins (serum total and HDL cho-
lesterol and triglycerides) were deter-
mined by standardized assays at each
center. All initially non–insulin-requiring
patients were tested for GADA in a central
laboratory (London) as part of the Euro-
pean Union Action LADA program.
Diagnostic criteria for metabolic
syndrome
Metabolic syndrome was assessed accord-
ing to the NCEP criteria (6) as follows:
waist circumference102 cm in men and
88 cm in women, triglycerides 1.70
mmol/l, HDL cholesterol 1.00 mmol/l
in men and 1.30 mmol/l in women,
blood pressure 130/85 mmHg or taking
antihypertensive medication, and fasting
glucose 6.1 mmol/l. We chose to iden-
tify all diabetic patients in this study as
fulfilling the criteria for hyperglycemia.
Three of five criteria were required for the
diagnosis of metabolic syndrome. Be-
cause raised glucose is one criterion for
metabolic syndrome and all diabetic pa-
tients, by definition, have raised glucose,
we reanalyzed the data, excluding glucose
as a variable.
Antibody measurement
The radioimmunoprecipitation assay for
GADAs uses human islet GAD65 cDNA
with in vitro transcription and translation
systems as described previously (12). All
samples were centrally tested in London
in duplicate, including positive and neg-
ative control standard sera. Each assay for
GADA included in-house standard serum
from a pre-diabetic individual serially di-
luted to an end point equivalent at 70
World Health Organization (WHO) units
above which samples were scored posi-
tive. A separate positive serum sample
(equivalent to the WHO standard of 200
WHO IU) was used as an in-house control
to standardize each assay for unit calcula-
tion. In the Diabetes Antibody Standard-
ization Program Antibody Workshop our
assay had a sensitivity of 74% and speci-
ficity of 98% for GADAs (13). In the latest
Diabetes Antibody Standardization Pro-
gram workshop (2007) our assay had a
sensitivity of 80% and specificity of 98%
for GADAs (M.I.H., R.D.L., unpublished
data). Positive samples were retested to
confirm GADA positivity and reduce the
false-positive rate. To compare the preva-
lence of metabolic syndrome with respect
to the GADA titer in patients with LADA,
we sought to divide them into two sub-
groups using a Q-Q plot of GADA-
positive patients.
Statistical analyses
The differences between groups were an-
alyzed with a 2 test or Fisher’s exact test
when appropriate. Quantitative variables
were analyzed with a general linear model
univariate, and a post hoc analysis was
performed with a Bonferroni test; data are
presented as means  SD. A logistic re-
gression analysis was performed to evalu-
ate confounding by covariables, with
adjustment for sex, age of onset, disease
duration, and ethnicity to calculate the
odds ratio (OR) for metabolic syndrome;
three dummy variables were created to
include three groups of patients with con-
trol subjects as a reference group. Data are
presented as ORs with 95% CIs. Values
for GADA levels, triglycerides, and HDL
cholesterol were log-transformed to nor-
malize distributions. All analyses were
performed using SPSS for Windows
(SPSS, Chicago, IL). P 0.05 was consid-
ered statistically significant. Q-Q proba-
bility plots were used to analyze the
distribution of GADA measurements for
normality. Observed antibody values
were plotted along the horizontal axis
against expected normal values under
normality on the vertical axis using
Blom’s proportion estimation formula.
The study protocol is in accordance with
the Declaration of Helsinki and was ap-
proved by local ethics committees in each
study center. Informed written consent
was obtained from all subjects before
blood sampling.
RESULTS— Of the 2,011 subjects
studied, for diabetic patients (n 1,652),
mean  SD age was 52.7  10.3 years,
duration of diabetes was 5.2 6.7 years,
and 51.8% were men. For control sub-
jects (n 359), age was 53.5 10.7 years
and 51.0% were men. The demographics
of the different groups are shown in Table
1. Of note, age was significantly lower in
patients with type 1 diabetes (43.8 9.8
years) than in those with LADA (49.7 
10.4 years) (P 0.0001) and in both was
lower than for type 2 diabetic patients
(55.1  10.1 years) (P  0.0001). Clini-
cal and biochemical features of each
group are shown in Table 2.
The prevalence of metabolic syn-
drome, including hyperglycemia as a
component, was 75.5% in all diabetic pa-
tients and 26.5% in control subjects (P
0.0001). Metabolic syndrome was de-
tected in significantly more patients with
type 1 diabetes (31.9%) and LADA
(41.9%) than in control subjects (P 
0.006). Referring to control subjects, the
ORs (95% CI) for metabolic syndrome are
as follows: for type 2 diabetes 22.5 (15–
33.7) (P  0.0001); for LADA 2.2 (1.2–
3.6) (P  0.004); and for type 1 diabetes
1.1 (0.7–1.9) (P  0.6). There was a sig-
nificant difference in the OR between type
1 diabetes and LADA for metabolic syn-
Hawa and Associates
DIABETES CARE, VOLUME 32, NUMBER 1, JANUARY 2009 161
drome, even after correction for age, du-
ration of disease, sex, and ethnicity: 3.2
(1.2–8.3) (P 0.015). The prevalence of
metabolic syndrome was higher in type 2
diabetic patients (88.8%) than in patients
with either LADA (41.9%) or type 1 dia-
betes (31.6%) (P 0.0001 for both com-
parisons). No differences were seen in sex
for metabolic syndrome (50% men vs.
50% women). The risk of metabolic syn-
drome increases with age: 1.05 (1.04–
1.06) per year (P  0.0001).
When glucose was excluded as a vari-
able, metabolic syndrome was not more
prevalent in patients with autoimmune
diabetes (type 1 diabetes and LADA)
(17.3%) than in control subjects (23.7%)
but remained more prevalent in type 2
diabetic patients (47.8%) (P  0.001 for
all groups). Metabolic syndrome was less
prevalent in patients with type 1 diabetes
(16.9%) than in those with LADA
(25.0%) or control subjects (23.7%) (P
0.04), and the prevalence was similar in
the two latter groups (P  0.7). For con-
trol subjects the ORs (95% CI) were as
follows: for type 2 diabetes 2.4 (1.6–3.6)
(P 0.0001); for LADA 0.9 (0.50–1.60)
(P  0.69); and for type 1 diabetes 1.1
(0.39–1.12) (P 0.60). The frequency of
metabolic syndrome for all groups was
still similar in men (53.1%) and women
(46.9%) (P 0.45). The risk of metabolic
syndrome still increased with age: 1.02
(1.01–1.03) per year (P 0.0001). It fol-
lows that factors associated with meta-
bolic syndrome include diabetes and
older age and, when glucose is excluded
as a trait, type 2 diabetes and older age.
Of the individual components of the
metabolic syndrome, after adjustment for
age of onset, duration of disease, sex, and
ethnicity, waist circumference was similar
in patients with type 1 diabetes and LADA
(P 0.44) but was lower in each of these
groups than in patients with type 2 diabe-
tes (P  0.0001 for both comparisons),
systolic and diastolic blood pressures
were similar in patients with type 1 dia-
betes and LADA (P 0.28 and P 0.49,
respectively) but was lower in each of
these groups than in patients with type 2
diabetes (P 0.0001), triglycerides were
similar in patients with type 1 diabetes
and LADA (P 0.63) but lower in each of
these groups than in patients with type 2
diabetes (P  0.0001), and HDL choles-
terol was similar in patients with type 1
diabetes and LADA (P  0.40) and in
both groups was higher than in patients
with type 2 diabetes (P 0.0001). Waist
circumference in the combined diabetes
groups (n  1,652) was directly associ-
ated with age at sampling (r  0.28; P 
0.0001) and inversely related with disease
duration (r0.28; P 0.0001). Of the
individual components, increases in waist
circumference (r  0.16; P  0.0001)
and systolic blood pressure (r 0.29; P
0.0001) and elevated triglycerides (r 
0.13; P 0.0001) but not diastolic blood
pressure (r 0.03; P 0.26) were more
common with increasing age, whereas
HDL cholesterol (r0.09; P 0.008)
decreased with age.
A Q-Q plot of GADA-positive patients
was performed to seek distinct popula-
tions, and we identified an inflection
point corresponding to 200 WHO IU
consistent with two modes (data not
shown). Further, a plot of the GADA titer
according to patient frequency revealed a
possible bimodality, and the lowest value
between the two modes was at a GADA
titer of 200 WHO IU (data not shown).
Therefore, we arbitrarily analyzed the
metabolic syndrome according to GADA
positivity in those with a GADA titer of
200 or200 WHO IU and found that it
was similar in LADA patients with high
(200 IU) (n 39) and low (70–200 IU)
(n  78) GADA titers (47.3 and 40.3%,
respectively) even after correction for age,
sex, duration of disease, and ethnicity
(P  0.37, 95% CI 0.29–1.6).
The frequency of features of meta-
bolic syndrome formed a hierarchy that
was similar in all the groups, irrespective
of the presence or type of diabetes, such
that high blood pressure elevated waist
circumference high triglycerides low
HDL cholesterol. Among those patients
with the metabolic syndrome, the most
frequent features of its components are
shown in Table 3. The cluster of hyper-
glycemia, increased waist circumference,
and high blood pressure was seen in
62.1% of those with the metabolic syn-
drome, whereas hyperglycemia, hyper-
tension, high triglycerides, and low HDL
cholesterol were seen in 17.9%.
CONCLUSIONS— These observa-
tions indicate that the metabolic syndrome
is a frequent finding in autoimmune diabe-
tes but is not more frequent in autoim-
mune diabetes than in normal subjects
when glucose is excluded as a risk factor.
In contrast, metabolic syndrome is far
more prevalent in type 2 diabetes, even
when glucose is excluded as a variable.
Whether glucose was or was not used as a
variable, we found that individual compo-
nents of the metabolic syndrome in both
patients with type 1 diabetes and those with
LADA were similar but in each group were
less than those seen in type 2 diabetic pa-
tients. It follows that there is no evidence
from this data set that autoimmune diabetes
is distinct in terms of prevalence of meta-
bolic syndrome from that in normal sub-
jects and the hypothesis that it would be
distinct is rejected. Nevertheless, metabolic
syndrome was more prevalent in patients
Table 1—Demographics of the groups
Normal
Type 1
diabetes LADA
Type 2
diabetes
n 359 288 117 1247
Female sex (%) 176 (49) 156 (54.2) 56 (47.8) 665 (53.3)
Age (years) 53.6  10.7* 43.8  9.8* 49.4  10.2* 55.1  9.1†
Age of onset (years) — 25.7  11.7* 47.1  10.4* 52.7  9.2*
Disease duration (years) — 18.2  11.7‡ 2.7  1.8‡ 2.4  1.8‡
Data are means  SD unless otherwise indicated. *P  0.0001: type 1 diabetes versus LADA and LADA
versus type 2 diabetes and controls. †P  0.043: type 2 diabetes versus controls. ‡P  0.0001: type 1
diabetes versus LADA and type 2 diabetes.
Table 2—Clinical and biochemical characteristics of each group of subjects
Normal
subjects
Type 1
diabetes LADA
Type 2
diabetes
Waist circumference (cm) 93.7  17 89.6  14.4 93  15.5 107.2  13.8
Systolic blood pressure (mmHg) 130.6  14.6 127.1  14.8 126.9  16.9 141.3  17.4
Triglycerides (mmol/l) 1.7  0.8 1.3  0.7 1.6  1.4 2  1.5
HDL cholesterol (mmol/l) 1.5  0.4 1.6  0.5 1.5  0.5 1.3  0.4
Data are means  SD.
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with LADA than in those with type 1 diabe-
tes when glucose was included as a variable.
Glucose is a debatable component of
the metabolic syndrome and was intro-
duced for assessing type 2 diabetes and
not type 1 autoimmune diabetes (14).
When glucose was excluded, the preva-
lence of metabolic syndrome in patients
with autoimmune diabetes was not
greater than that in normal subjects.
Therefore, there is no evidence to suggest
that autoimmune diabetes is due to de-
creased insulin sensitivity; instead, de-
creased insulin sensitivity might predispose
to an earlier time of diagnosis. Such de-
creased insulin sensitivity could explain
why age, overweight, and physical inactiv-
ity are as strongly predictive of LADA as
they are of type 2 diabetes (15,16). These
present observations indicate that meta-
bolic syndrome is as common in adults with
autoimmune diabetes as it is in normal sub-
jects. Thus, agents such as metformin and
other insulin sensitizers may be beneficial in
autoimmune diabetes, as they are in type 2
diabetes, in line with recent studies indicat-
ing that metformin is efficacious in type 1
diabetes (17).
Of the three current criteria for meta-
bolic syndrome (IDF, NCEP, and WHO),
we used the NCEP criteria because they
are more appropriate to apply here to
populations of variable geographical ori-
gin rather than the IDF criteria, for sim-
plicity, and the WHO criteria, which
include insulin resistance and microalbu-
minuria (6). Although it is possible that
metabolic syndrome should be defined
differently in autoimmune diabetes, in-
cluding type 1 diabetes and LADA, the
hierarchy of features associated with met-
abolic syndrome was similar to that found
in type 2 diabetic patients and control
subjects. Nevertheless, the metabolic syn-
drome was not originally introduced to
identify a feature of autoimmune diabetes
but to capture the clustering of a group of
continuous variables associated with car-
diovascular risk. That cluster has subse-
quently been extended to include measures
of endothelial dysfunction and low-grade
inflammation, but it remains unclear
whether these new parameters are also fea-
tures of autoimmune diabetes; for example,
type 2 diabetes is associated with increased
levels of proinflammatory serum cytokines
and acute-phase proteins, especially in as-
sociation with obesity, whereas in type 1
diabetes such inflammatory changes are
mild or nonexistent (18). Patients with
LADA have not been consistently found to
exhibit the systemic low-grade inflamma-
tion previously identified in type 2 diabetic
patients (18). Thus, it is reasonable to con-
clude that autoimmune diabetes, whether
type 1 diabetes or LADA, differs from type 2
diabetes with respect to systemic low-grade
inflammation, as it does with metabolic
syndrome.
Previous studies of metabolic syn-
drome in LADA have confirmed that, al-
though it is prevalent, it is less prevalent
than in type 2 diabetes (19,20). There are
only two previous studies comparing
LADA with type 1 diabetes, each suggest-
ing a tendency for LADA to have more
features of the metabolic syndrome, but
control subjects were not included; each
study was very small with a combined to-
tal of 94 patients with LADA and 112 type
1 diabetic patients, and one of them used
highly selected patients with LADA
(9,21). Large studies of type 1 diabetes
have identified a prevalence of metabolic
syndrome of 39% in Finnish patients,
which was approximately three times the
separately observed prevalence in nondi-
abetic Finnish subjects (22) and higher
than the frequency in American patients
with type 1 diabetes (22%) (23). How-
ever, in the latter study frequency of met-
abolic syndrome increased from 14.6 to
36.1% after a duration of diabetes of 9
years (23). It follows that there is a dy-
namic in the frequency of metabolic syn-
drome in autoimmune diabetes, whether
type 1 diabetes or LADA, which must be
considered in comparing the groups.
Therefore, the disparity in the prevalence of
metabolic syndrome between the Finnish
and American studies and our own Euro-
pean study probably reflects differences in
population characteristics including dura-
tion of diabetes, renal function, intensive in-
sulin therapy, male sex, and age, all of
which have been independently associated
with metabolic syndrome.
There is some limited evidence, other
than the clinical phenotype, to support
the contention that LADA is an interme-
diate form of diabetes between type 1 di-
abetes and type 2 diabetes. LADA, albeit
defined as GADA positivity irrespective of
therapy, was reported to be associated
with the CT and TT genotypes of the
TCFL2 gene and, therefore, apparently
shares genetic features with type 2 diabe-
tes (24). However, the high false-positive
rate of the GADA assay used in that study
raises issues regarding the validity of the
observation. We limited this potential er-
ror by repeating GADA assays in GADA-
positive subjects, thereby reducing the
risk of false positivity to 0.2%, much
less than the proportion of patients with
LADA. The error from not testing other
diabetes-associated autoantibodies is
probably small, given that 94% of patients
with LADA sampled from this cohort
were detected by GADA testing alone
(M.I.H., R.D.L., unpublished data). The
proposal that the metabolic syndrome is
more prevalent in patients with LADA who
also have a low GADA titer compared with
those with an arbitrarily selected high titer
of GADA was not confirmed in this present
study using a Q-Q plot to identify two ap-
parently distinct GADA-positive distribu-
tions (20). However, there is substantial
variation between laboratories with respect
to threshold GADA titers defining a positive
result, and caution should be exercised in
using such thresholds.
Thus, metabolic differences between
LADA and type 1 diabetes may not be cat-
egorical but part of a continuum, imply-
ing that LADA is one end of a rainbow of
a pathophysiological variation encom-
passing autoimmune diabetes (1). If we
accept the fact that metabolic syndrome is
a surrogate marker for insulin resistance,
there is now evidence that patients with
LADA are more insulin resistant than
adult type 1 diabetic patients but not
Table 3—Percentage of subjects with values over cutoff for each component of metabolic
syndrome
Normal subjects Type 1 diabetes LADA Type 2 diabetes
n 359 288 117 1,247
Glucose 6.7 100 100 100
Waist circumference 43.7 25.7 35.9 82.8
Systolic blood pressure 65.9 50.7 49.6 86.7
Triglycerides 39.6 23.6 35.8 49.8
HDL cholesterol 21.2 17 29 36.1
Patients with type 2 diabetes have a higher frequency of increased waist circumference and systolic blood
pressure. Patients with autoimmune diabetes (type 1 diabetes and LADA) tend to resemble normal subjects
for all features apart from increased blood glucose (although a fraction of normal subjects had impaired
fasting glucose).
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when glucose is excluded as a variable,
when insulin resistance in both is similar
to that in normal subjects. This conclu-
sion is important, as it implies that auto-
immune diabetes, whether type 1
diabetes or LADA, can be identified by
diabetes-associated autoantibodies, e.g.,
GADAs, as a categorical trait, irrespective
of individual components of the meta-
bolic syndrome or the need for insulin
treatment. Indeed, we have previously
suggested that insulin treatment is an in-
substantial feature to diagnose LADA be-
cause it is subject to local issues such as
medical practice and context, including
availability of GADA results (25). Thus,
the role of insulin resistance in autoim-
mune diabetes may be limited, and there
is no characteristic clinical phenotype of
adult-onset autoimmune diabetes; specif-
ically, neither forms of autoimmune dia-
betes showed an increased frequency of
metabolic syndrome in striking contrast
with type 2 diabetes.
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